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Abstract
The results of recent randomized trials to test the influence of antioxidants on coronary-event
rates and prognosis in patients with coronary-artery disease were disappointing. In none of
these studies did the use of vitamin E improve prognosis. In contrast, treatment of coronary-
artery disease with angiotensin-converting-enzyme (ACE) inhibitors reduced coronary-event
rates and improved prognosis. ACE inhibition prevents the formation of angiotensin II, which
has been shown to be a potent stimulus of superoxide-producing enzymes in atherosclerosis.
The findings suggest that inhibition of superoxide production at enzymatic levels, rather than
symptomatic superoxide scavenging, may be the better choice of treatment.
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The oxidative-stress concept of
atherosclerosis: the rationale for the use of
antioxidants
The endothelium-derived relaxing factor, recently identified
as nitric oxide (NO [1]) or a closely related compound [2],
has potent antiatherosclerotic properties. NO released
from endothelial cells works in concert with prostacyclin to
inhibit platelet aggregation; it inhibits the attachment of
neutrophils to endothelial cells and the expression of
adhesion molecules. NO in high concentrations inhibits
the proliferation of smooth-muscle cells. Therefore, under
all conditions where an absolute or relative NO deficit is
encountered, the process of atherosclerosis is being initi-
ated or accelerated. The half-life of NO, and therefore its
biological activity, is decisively determined by oxygen-
derived free radicals such as superoxide (O2
–) [3]. Super-
oxide reacts rapidly with nitric oxide (NO) to form the
highly reactive intermediate peroxynitrite (ONOO–). The
rapid bimolecular reaction between NO and O2
–, yielding
ONOO– (rate constant 1.9×1010/M/s), is about 5 to 10
times faster than the dismutation of O2
– by superoxide dis-
mutase. Therefore, ONOO– formation represents a major
potential pathway of NO reactivity depending on the rates
of tissue O2
– production. Peroxynitrite is also a highly reac-
tive intermediate that may cause oxidative damage to
lipids, proteins, and DNA.http://cvm.controlled-trials.com/content/1/1/038
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There is a growing body of evidence that endothelial dys-
function in the setting of hypercholesterolemia, diabetes
mellitus, hypertension, or chronic smoking is often a con-
sequence of enhanced NO degradation by oxygen-derived
free radicals rather than diminished NO formation due to
decreased activity and/or expression of the nitric oxide
synthase. Therefore, in many instances the most effective
approach to improve NO bioavailability in the presence of
risk factors is to lower O2
– levels, eg by treatment with
scavenging agents or by the administration of drugs that
specifically inhibit O2
– production.
Effects of antioxidants in clinical studies
The effects of antioxidants such as vitamin C, a- and
b-carotene, or vitamin E on the prognosis in patients with
coronary-artery disease are very disappointing. So far,
there is just one study showing a reduction in coronary-
event rates in patients with angiographically evident coro-
nary-artery disease (the Cambridge Heart Antioxidant
Study [CHAOS] trial) after treatment with vitamin E
(400–800IU/day), although the overall prognosis in these
patients was not improved [4]. Other randomized trials,
such as the Alpha-Tocopherol, Beta Carotene Cancer
Prevention Study [5], the Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto miocardico (GISSI-Preven-
zione trial) [6], and the Heart Outcomes Prevention Evalu-
ation (HOPE) [7] study, failed to demonstrate any
improvement of the prognosis in patients with coronary-
artery disease.
How can one explain the lack of benefit from antioxidants
despite the known causal role of oxidative stress in the ini-
tiation and progression of atherosclerosis? Vitamins scav-
enge free radicals. However, the rate constant for the
reaction of vitamins E and C with O2
– is much slower
(1000- to 10000-fold) than the rate constant for the reac-
tion between NO and O2
–. Therefore, in order to scavenge
O2
–, antioxidants must be administered in very high con-
centrations, to reach compartments where O2
– is formed
(such as endothelial and smooth-muscle cells). When high
concentrations of vitamins are used, however, pro-oxidative
effects may come into play. For example, low concentra-
tions of vitamin E improved endothelial function in choles-
terol-fed animals, while high concentrations of the vitamin
had the opposite effects and even worsened endothelial
function [8]. One explanation for this is that when
vitamin E reacts with a radical, it becomes the vitamin-E
radical, ie the tocopheroxyl radical, which itself may partici-
pate in pro-oxidative events. These findings may indicate
that the optimal dose of antioxidants must be titrated in
order to improve rather than worsen vascular function. The
phenomenon may at least partly explain the failure of
antioxidants to improve prognosis in patients with coro-
nary-artery disease. It is also possible that combinations of
antioxidants, such as vitamins C and E, need to be used to
prevent accumulation of the vitamin-E radical.
Are angiotensin-converting-enzyme inhibitors
the better ‘antioxidants’?
The effect of angiotensin-converting-enzyme (ACE)
inhibitors on the progression of atherosclerosis and
endothelial function has been studied in several animal
models and in patients with coronary-artery disease. It has
been consistently shown that ACE inhibition slows the
progression of atherosclerosis [9] and improves impaired
endothelial dysfunction [10] without altering plasma chol-
esterol levels. In contrast to the published findings in
studies of antioxidants, ACE inhibitors seem to have a
beneficial influence on the prognosis in patients with coro-
nary-artery disease [11]. How do ACE inhibitors benefi-
cially influence vascular function in atherosclerosis? ACE
inhibition prevents formation of angiotensin II, one of the
most potent vasoconstrictors. Angiotensin II, in turn, stimu-
lates the release of endothelin-1 from endothelial cells and
induces the expression of the preproendothelin gene in
endothelial and smooth-muscle cells. Another important
aspect is that endothelial kininase II is identical with ACE.
Inhibition of kininase II, which is responsible for the break-
down of bradykinin, leads to high local concentrations of
bradykinin. This substance, in turn, is a potent stimulus for
the release of endothelium-derived hyperpolarizing factor,
NO, and prostacyclin. A novel, recently identified, mecha-
nism contributes to the detrimental effects of angiotensin II
on vascular superoxide production. Angiotensin II has
been shown to increase vascular superoxide production
by activating an NADH-driven oxidase [12], one of the
most significant superoxide-producing enzymes in
endothelial and smooth-muscle cells. Recent studies with
hypercholesterolemic animals [13] and patients with coro-
nary-artery disease [14] indicate that activation of this
enzyme contributes considerably to endothelial dysfunc-
tion and early plaque formation.
The stimulatory effects of angiotensin II on the activity of
the HADH-driven oxidase would suggest that in the pres-
ence of an activated renin–angiotensin system (local or
circulating), vascular dysfunction due to increased vascu-
lar superoxide production is likely.
Indeed, there is a large body of literature providing
evidence that the renin–angiotensin system is causally
linked to the development and progression of athero-
sclerosis. Incubation in vitro of cultured smooth-muscle
cells with native low-density lipoproteins (LDLs) increases
the expression of the angiotensin II receptor subtype AT1
[15]. Similar phenomena have been observed in animals
fed cholesterol [16], in animals that are hyperlipidemic
because of an LDL-receptor defect [13], and in patients
with hypercholesterolemia [17]. Macrophages in athero-
sclerotic plaques produce large amounts of angiotensin II.
The activity of the ACE is increased in response to oxida-
tive stress. Angiotensin II facilitates the recruitment of
monocytes/macrophages into the vessel wall by stimulatingCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Warnholtz and Münzel
the production of the monocyte chemoattractant protein
(MCP-1) and vascular-adhesion molecules.
Further indirect support for the involvement of the
renin–angiotensin system in the development of athero-
sclerosis was provided by studies testing the antiathero-
sclerotic properties of ACE inhibitors and of AT1-receptor
antagonists. These studies have shown that both treat-
ment regimens beneficially influence endothelial function
[9], reduce oxidative stress within vascular tissue by
inhibiting the vascular NADH oxidase, and, therefore,
retard the formation of atherosclerotic plaques [13].
The recently published results of the HOPE study seem to
strengthen the idea that inhibition of the renin–angiotensin
system [11], rather than treatment with the classical
antioxidant  a-tocopherol, beneficially affects the prognosis
in patients with coronary-artery disease [7]. Treatment
with ramipril significantly lowered the risk of cardiovascular
mortality and nonfatal cardiovascular events in high-risk
patients who had vascular disease or diabetes plus one
known cardiovascular risk factor. Thus, it may be con-
cluded that inhibition of the renin–angiotensin system and
the subsequent inhibition of superoxide-producing
enzymes provide a better antioxidative regimen than the
administration of classic antioxidants, which merely scav-
enge already formed reactive oxygen species.
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